Women are twice as likely as men to be affected by Alzheimer's and multiple sclerosis, and often suffer from cognitive impairments, so-called "brain fog," during menopause. A new study led by Rhonda Voskuhl, professor of neurology at the University of California, Los Angeles (UCLA), provides groundbreaking insights into the reasons for these gender differences and shows promising approaches for new treatment methods.
The study, published in Science Translational Medicine, identifies a gene on the X chromosome that triggers an increased inflammatory response in the brain in women. Since women have two X chromosomes, the double activity of this gene leads to an increased risk of diseases such as Alzheimer's, multiple sclerosis and cognitive impairments related to menopause. Through experiments on mice, the research team was able to show that switching off this gene in certain brain cells reduces neuropathological changes and disease symptoms.
Another key factor is the hormone estrogen, which has anti-inflammatory effects and protects cognitive function. During menopause, when estrogen levels drop, this protective mechanism is weakened, which increases inflammatory processes in the brain and leads to symptoms such as memory loss or difficulty concentrating. These findings open up new possibilities for targeted therapies, particularly through hormone-based approaches that directly affect the brain.
The study highlights the potential of innovative treatment methods such as PearlPAK®, a product of the company CleopatraRX™, which specifically targets the cognitive challenges during menopause. Such therapies could improve the quality of life for millions of women by reducing inflammation in the brain and promoting cognitive health.
Dr. Rhonda Voskuhl, a leading expert on gender differences in the brain, emphasizes the importance of this discovery for the development of gender-specific therapies. CleopatraRX™, a company specializing in women's health, is working on personalized solutions made accessible through telemedicine to effectively treat cognitive symptoms in midlife.
Source: CleopatraRX
